本文關(guān)鍵詞：紫杉醇脂質(zhì)體與傳統(tǒng)紫杉醇治療卵巢癌的療效及不良反應(yīng)分析　出處：《泰山醫(yī)學(xué)院》2014年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 卵巢癌 紫杉醇脂質(zhì)體 傳統(tǒng)紫杉醇 卡鉑 療效 不良反應(yīng)

【摘要】：研究目的 對(duì)紫杉醇脂質(zhì)體聯(lián)合卡鉑和傳統(tǒng)紫杉醇聯(lián)合卡鉑兩種化療方案治療卵巢癌的療效及不良反應(yīng)進(jìn)行分析，評(píng)價(jià)兩方案的利弊，尋求更優(yōu)化的卵巢癌化療方案。 研究方法 收集2012.6-2013.12在本院治療的卵巢癌患者65例。所有患者均接受過(guò)卵巢腫瘤細(xì)胞減滅術(shù)，，術(shù)后病理確診為原發(fā)性上皮性卵巢癌。將患者分為觀察組和對(duì)照組，觀察組（30例）予以紫杉醇脂質(zhì)體（力樸素）（135～175mg/m2）聯(lián)合卡鉑方案化療，對(duì)照組（35例）予以傳統(tǒng)用紫杉醇（135～175mg/m2）聯(lián)合卡鉑方案化療，每3周為1個(gè)周期，共6個(gè)周期。 研究結(jié)果 紫杉醇脂質(zhì)體聯(lián)合卡鉑與紫杉醇聯(lián)合卡鉑兩種化療方案比較在卵巢癌總體有效率方面兩組差異無(wú)統(tǒng)計(jì)學(xué)意義（P=0.324）；但是兩者在某些化療不良反應(yīng)方面差異有統(tǒng)計(jì)學(xué)意義。紫杉醇脂質(zhì)體聯(lián)合卡鉑在降低肌肉關(guān)節(jié)痛（P=0.013）、周圍神經(jīng)毒性（P=0.023）、呼吸困難（P=0.022）、惡心/嘔吐（P=0.007）、面部潮紅（P=0.029）及皮疹（P=0.021）、脫發(fā)（P=0.020）等不良反應(yīng)的發(fā)生率明顯少于紫杉醇聯(lián)合卡鉑。但在腹瀉、腹痛及血液系統(tǒng)等不良反應(yīng)方面，兩組的差異無(wú)統(tǒng)計(jì)學(xué)意義。 研究結(jié)論 現(xiàn)有的臨床證據(jù)顯示，紫杉醇脂質(zhì)體聯(lián)合卡鉑與紫杉醇聯(lián)合卡鉑治療卵巢癌療效相當(dāng)，且相對(duì)安全。因此，紫杉醇脂質(zhì)體聯(lián)合卡鉑化療方案可以作為治療卵巢癌的一種新的、安全、有效的方法。由于本次研究的樣本量較小，上述結(jié)論尚需大樣本的隨機(jī)雙盲對(duì)照試驗(yàn)進(jìn)一步證實(shí)。
[Abstract]:research objective
The efficacy and side effects of two chemotherapy regimens of paclitaxel liposome combined with carboplatin and traditional paclitaxel combined with carboplatin were analyzed. The pros and cons of the two program were evaluated, and a more optimized chemotherapy plan for ovarian cancer was sought.
research method
Collect 2012.6-2013.12 in 65 cases of patients with ovarian cancer. All patients received the ovarian cytoreductive surgery, postoperative pathology confirmed the diagnosis of primary epithelial ovarian cancer. The patients were divided into observation group and control group, the observation group (30 cases) of paclitaxel liposome (Li Pu (Su) 135 ~ 175mg/m2) and carboplatin chemotherapy, the control group (35 cases) treated by traditional paclitaxel (135 ~ 175mg/m2) and carboplatin, every 3 weeks for 1 cycles, 6 cycles.
Research results
Two kinds of chemotherapy of paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin in ovarian cancer overall efficiency difference between the two groups was not statistically significant (P=0.324); but the two in some adverse reactions in chemotherapy. There was a significant difference of paclitaxel liposome combined with platinum card in reducing muscle and joint pain (P=0.013), peripheral neurotoxicity (P=0.023) (P=0.022), dyspnea, nausea / vomiting (P=0.007), facial flushing (P=0.029) and skin rash (P=0.021), alopecia (P=0.020) and other adverse reactions were significantly less than paclitaxel combined with carboplatin. But in diarrhea, abdominal pain and adverse reactions of blood system, no statistically significant difference between the two group.
research conclusion
Current clinical evidence shows that a paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin is effective in the treatment of ovarian cancer, and relatively safe. Therefore, paclitaxel liposome combined with chemotherapy can be used as a new, safe and effective for the treatment of ovarian cancer, the method in this study. The sample size is small, this conclusion still needs a large sample randomized double-blind controlled trial further confirmed.

【學(xué)位授予單位】：泰山醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 張桂萍;;多烯紫杉醇聯(lián)合順鉑治療晚期卵巢癌臨床觀察與護(hù)理[J];貴州醫(yī)藥;2010年11期

2 譚理慧;昌燕華;王喜華;;紫杉醇聯(lián)合順鉑不同給藥途徑治療晚期卵巢癌的療效觀察[J];腫瘤藥學(xué);2012年01期

3 孔繁宏;董慶芬;曹曉剛;;紫杉醇脂質(zhì)體聯(lián)合順鉑治療晚期非小細(xì)胞肺癌的臨床觀察[J];實(shí)用癌癥雜志;2007年05期

4 樸金霞;浦建文;王旭輝;;高齡卵巢癌52例的手術(shù)治療及圍手術(shù)期治療[J];中國(guó)婦幼保健;2008年16期

5 周衛(wèi),呂琦,翁幗英;紫杉醇脂質(zhì)體在大鼠體內(nèi)的藥動(dòng)學(xué)[J];中國(guó)藥科大學(xué)學(xué)報(bào);2000年06期

6 謝肖蘭,李力;晚期卵巢上皮性癌先期化學(xué)藥物治療的研究現(xiàn)狀[J];中華婦產(chǎn)科雜志;2003年02期

7 成海燕;陳秀瑋;;紫杉醇脂質(zhì)體與紫杉醇治療100例卵巢癌分析[J];中國(guó)腫瘤;2008年08期

8 吳洪斌;紫杉醇注射液不良反應(yīng)的預(yù)防及處理[J];中國(guó)新藥雜志;2002年02期

本文編號(hào)：1431411